登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由青海大学附属医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06200168,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Patients with breast cancer, with no restrictions on molecular typing; early-stage patients must not have undergone prior chemotherapy, while advanced-stage patients must be candidates for first-line chemotherapy and have declined neoadjuvant or adjuvant chemotherapy for over 3 months. All patients must receive highly emetogenic chemotherapy (HEC) based on anthracycline chemotherapy with cyclophosphamide (EC or AC) or carboplatin (AUC≥4)/cisplatin;
入选标准第 3 条
Received or is scheduled to receive radiation therapy to the abdomen, pelvis, head and neck within 1 week prior to Day 1 or between Days 1 to 5 in cycle 1;
排除标准第 4 条
Received acupuncture treatments for any conditions less than 4 weeks before HEC;
排除标准第 14 条
Eastern Cooperative Oncology Group performance status of 0-2;
入选标准第 2 条
Patients who are pregnant or breast-feeding;
排除标准第 10 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06200168,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Aged 18 years or older and aged 75 years or younger, of any nationality; Eastern Cooperative Oncology Group performance status of 0-2; Patients with breast cancer, with no restrictions on molecular typing; early-stage patients must not have undergone prior chemotherapy, while advanced-stage patients must be candidates for first-line chemotherapy and have declined neoadjuvant or adjuvant chemotherapy for over 3 months. All patients must receive highly emetogenic chemotherapy (HEC) based on anthracycline chemotherapy with cyclophosphamide (EC or AC) or carboplatin (AUC≥4)/cisplatin; Predicted life expectancy of ≥3 months; Adequate bone marrow, kidney, and liver function; Adequate contraception if premenopausal women; Written informed consent by the patient before enrolment.排除标准:Exclusion Criteria:
Patients already submitted to chemotherapy; Is scheduled to receive any non-HEC on Day 1; Is scheduled to receive any chemotherapy on days 2-4 after HEC; Received or is scheduled to receive radiation therapy to the abdomen, pelvis, head and neck within 1 week prior to Day 1 or between Days 1 to 5 in cycle 1; Has symptomatic primary or metastatic symptomatic central nervous system malignancy causing nausea and/or vomiting; Have ongoing emesis or CTCAE grade 2 or greater nausea; Significant medical or mental conditions; Any allergies to study drug, antiemetics or dexamethasone; Significantly abnormal laboratory values (platelets, coagulation indexes, absolute neutrophils, AST, ALT, bilirubin or creatinine); Patients who are pregnant or breast-feeding; Inflammatory skin reaction; Has lymphedema in acupuncture stimulation area; Patients who are afraid of electroacupuncture stimulation or allergic to stainless steel needles; Received acupuncture treatments for any conditions less than 4 weeks before HEC; Currently using drugs with antiemetic activity (e.g., 5-HT3 receptor antagonists, corticosteroids (except when used at physiological doses), dopamine receptor antagonists, minor tranquilizers, antihistamines, and benzodiazepines (except for nocturnal sedation)); Patients with concomitant severe diseases or with a predisposition to emesis such as gastrointestinal obstruction, active peptic ulcer, and hypercalcemia and symptomatic brain metastasis; Has a convulsive disorder requiring anticonvulsant treatment; Patients administered thioridazine as a chronic antipsychotic medication (patients are allowed to receive prochlorperazine and other phenothiazines as a rescue antiemetic treatment); Concurrent treatment with quinolone antibiotics; Has a history of chronic alcoholism (determined by the investigator); Known arrhythmias, uncontrolled congestive heart failure, or acute myocardial infarction within the past six months; Has a history of uncontrolled diabetes (e.g., using insulin or oral hypoglycemic agents).
引自 ClinicalTrials.gov, NCT06200168, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06200168,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。